January 25, 2026 — Mumbai & New York — Sun Pharmaceutical Industries Ltd. (Sun Pharma), India’s largest pharmaceutical company, has submitted a non‑binding proposal to acquire Organon & Co., a U.S.‑based healthcare company focused on women’s health, biosimilars, and branded medicines. The proposal, reported this week in global financial media, underscores Sun Pharma’s strategic intent to significantly expand its footprint in the U.S. pharmaceutical market and enhance its position in specialty and innovative therapeutic segments.
If completed, the transaction — which market sources estimate could be valued at approximately $10 billion–$14 billion including debt financing — would represent the largest cross‑border acquisition by an Indian pharmaceutical company and a defining milestone in Sun Pharma’s global growth trajectory.
“Sun Pharma’s proposal for Organon reflects our ambition to expand into higher‑growth specialty markets and augment our global platform with established brands and capabilities,” said a company insider familiar with the matter. “While the offer is non‑binding and discussions are preliminary, this strategic initiative highlights our commitment to accelerating growth in the world’s largest regulated healthcare market.”
Strategic Rationale and Market Impact
- Expanded U.S. Presence: Organon’s established portfolio in women’s health and biosimilars would provide Sun Pharma with a broader platform in high‑growth therapeutic areas and an enhanced commercial presence in the United States.
- Complementary Therapies and Brands: The acquisition target’s mix of established branded products and biosimilar offerings aligns with Sun Pharma’s strategy of combining specialty pharmaceuticals with scalable global assets.
- Market Confidence: Organon’s stock has shown notable share price gains in recent sessions amid takeover speculation, indicating investor recognition of the potential strategic value of such a transaction.
- Debt Considerations: Organon carries a significant debt load, which has been cited by analysts as an important factor in evaluating the economics and risk profile of the potential deal.
Sun Pharma’s board and Organon’s leadership would need to progress through further due diligence, formal offers, and regulatory approvals for any definitive agreement to be finalized. At present, both companies have not confirmed terms or provided official comments on the proposed transaction.
Market and Competitive Context
This development comes as global pharmaceutical companies increasingly pursue strategic mergers and acquisitions to build scale, diversify portfolios, and navigate competitive pressures in the U.S. and global markets. A successful acquisition of Organon by Sun Pharma would mark a transformative shift in cross‑border deals and further establish India’s pharmaceutical sector as a major participant in global biopharma consolidation.
About Sun Pharmaceutical Industries Ltd.
Founded in 1983 and headquartered in Mumbai, India, Sun Pharma is a global pharmaceutical leader specializing in branded and generic medicines across therapeutic areas including cardiology, oncology, dermatology, and central nervous system disorders.
About Organon & Co.
Organon & Co. is a U.S.-based healthcare company focused on women’s health, established brands, and biosimilars. The company was spun off from Merck & Co. in 2021 and continues to operate as a diversified global pharma organization.
By